Table 1. Study characteristics of the included studies.
| Study | Design | Disease | Gender (M/F) |
Age (y) |
Eyes (n) |
Intervention |
Follow-up (mo) | NOS | ||||
| IDI | IVA | IDI | IVA | IDI | IVA | IDI | IVA | |||||
| Aksoy 2020[17] | Retrospective cohort study | DR | 18/19 | 18/16 | 61.3±11.3 | 59.3±10.3 | 37 | 34 | 0.7 mg at baseline | 3 injections/mo (2 mg) | 6 | 6 |
| Bolukbasi 2019[18] | Retrospective cohort study | DR | 9/16 | 13/19 | 65.1±13.2 | 56.4±13.5 | 25 | 32 | 0.7 mg at baseline | 3 injections/mo (2 mg) | 3 | 5 |
| Comet 2021[19] | Non-RCT | DR | 12/9 | 11/9 | 66.3±7.8 | 69.6±9.2 | 21 | 20 | 0.7 mg +PRN | 3 injections/mo (2 mg)+ PRN | 12 | N/A |
| Hanhart 2017[20] | Retrospective cohort study | RVO | 6/4 | 6/6 | 63.60±7.12 | 62.08±8.87 | 10 | 12 | NA | NA | 12 | 7 |
| Kaldirim2018[21] | Retrospective cohort study | RVO | 12/8 | 13/7 | 70.6±3.9 | 70.45±3.9 | 20 | 20 | 0.7 mg at baseline | 3 injections/mo (2 mg)+ PRN | 6 | 6 |
| Ozsaygili 2020[22] | RCT | DR | 15/14 | 20/13 | 64.8±7.9 | 66.4±2.0 | 48 | 50 | 0.7 mg +PRN | 3 injections/mo (2 mg)+ PRN | 12 | N/A |
| Yucel 2019[23] | Retrospective cohort study | RVO | NA | NA | 65.4±2.3 | 66.2±3.2 | 24 | 16 | PRN (0.7 mg) | PRN (2 mg) | 6 | 6 |
M: Male; F: Female; RCT: Randomized controlled trial; DR: Diabetic retinopathy; RVO: Retinal vein occlusion; IDI: Intravitreal dexamethasone implant; IVA: Intravitreal aflibercept; NA: Not applicable; NOS: Newcastle-Ottawa scale; PRN: pro re nata.